Emcure Pharmaceuticals Limited

Other

Samit Satish Mehta

Mukund Keshav Gurjar

Narendra Kumar Tripathy

Golakchandra Sudarshan Maikap

Swapnil Panditrao Sonawane

Shashikant Gangaram Joshi

Rajendra Dagesing Mahale

Prasad Pandurang Panchabhai

Pravin Prabhakar Ahirrao

Sanjay Shankar Pawar

Tushar Pandurang Khaladkar

Ashok Tukaram Chaudhari

Prabhakaran Balasubramanian

Vijay Keshav Kalhapure

Gulabrao Dagadu Patil

Shivnath Bhaupatil Shinde

Pankaj Shalikrao

Deepak Pragjibhai Gondaliya

Hiren Pravinbhai Patel

Neha Manubhai Patel

Sachin Arvind Badhe

Arpan Suresh Chudasama

Haresh Ishwarbhai Patel

Raghuramireddy Baireddy

Srinivas Nandala

Sandeep Anilrao Kotharkar

Pankaj S Patil

Neelakandan Kaliaperumal

Nandala Srinivas

Chinmoy Mriganka Pramanik

Balaji R Mugale

Vemavarapu P K V Rao

Pradip Nana Patil

Sandip B Buchude

Kiran Avinash Bapat

Devising Pardeshi

Satyajeet Binay Biswas

Sachin Aravind Badhe

Mangesh Kamble

Lakindrasing Girase

Jitendra Mohansingh Baweja

Manoj Kumar Thottasseri

Mangesh Gorakhanath Kamble

Sandip Tanaji Salunkhe

Kaliaperumal Neelakandan

Balaji Ram Mugale

Sandip Bajaba Buchude

Pankaj Shalikrao Patil

Balaji Vasant Chaugule

Ganesh Kaluram Karhade

Kaliyaperumal Neelakandan

Ajit Sahebrao Borhade

Jayendra Dattatraya Patole

Pankaj Shallkrao Patil

Devising Rameshsing Pardeshi

The present invention provides a process for preparation of trientine dihydrochloride (1) comprising reaction of protected triethylene tetramine with hydrochloric acid in an aqueous system to yield the dihydrochloride salt wherein the formation of inorganic impurities and undesired salts is controlled significantly.

Process for preparation of trientine dihydrochloride

The present invention relates to a stable liquid formulation of cabazitaxel. The formulation comprises cabazitaxel and at least one solubilizer. Typically, formulations are in the form of ready-to-use solutions or concentrates.

Liquid formulation of cabazitaxel

The present invention provides a process for preparation of {(2E,4E,6E,8E)-9-(4-methoxy-2,3,6-trimethyl)phenyl-3,7-dimethyl-nona-2,4,6,8}tetraenoate, an acitretin intermediate of formula (VI) with trans isomer &#x2265;97%, comprising of reacting 3-formyl-crotonic acid butyl ester of formula (V), substantially free of impurities, with 5-(4-methoxy-2,3,6-trimethylphenyl)-3-methyl-penta-2,4-diene-1-triphenyl phosphonium bromide of formula (IV) and isolating resultant compound of formula (VI), treating the filtrate with iodine for isomerization of the undesired cis intermediate and finally obtaining acitretin (I), with desired trans isomer &#x2265;97%.

Process for preparation of acitrecin

A process for preparation of diethyl 2-aetamido-2-(4-octyl phenyl)ethyl malonate (III), a key intermediate of fingolimod hydrochloride comprising reaction of 2-(4-octylphenyl)ethyl iodide (IV) with diethyl acetamido malonate in presence of a base and an iodinating agent and in an organic solvent. The compound of formula (III) thus obtained provided fingolimod hydrochloride (Ia) having associated impurities below the regulatory limits.

Fingolimod hydrochloride process

The present invention relates to the preparation of stable pyridone disulphide derivatives having general formula (I) and its stereoisomers, which are useful in the treatment of gastrointestinal disorders. Pyridone disulphide derivatives (I) wherein, R, Rand Rare independently alkyl, alkoxy, halogen, halogenated alkoxy, halogenated alkyl, hydrogen and could be the same or different and X is CH or N. Ris methyl, methoxy, fluorine, trifluoromethyl, difluoromethoxy and hydrogen, Ris methyl, methoxy and hydrogen, and Ris methyl and hydrogen.

Pyridone derivatives as acid secretion inhibitors and process for preparation thereof

Controlled release oral dosage formulations containing calcium channel blocker and processes for preparation thereof, are provided for once a day treatment. The active agent is preferably a dihydropyridine calcium channel blocker, such as nisoldipine. In one embodiment, the formulation provides controlled release of micronized nisoldipine with one or more pH independent release controlling polymers. The controlled release matrix formulation is advantageous and can be prepared by a simple, economically viable process as compared to complex core-coat prior-art versions.

Controlled release formulations of nisoldipine

The present invention relates to a novel synthetic route for the preparation of raltegravir and pharmaceutically acceptable salts, starting from 2-amino-2-methylpropanenitrile and oxadiazole carbonyl chloride, through the formation of a pyrimidinone intermediate of formula (V).

Synthesis of Raltegravir

Synthesis of raltegravir

The present invention provides a convenient and industrially viable process for preparation of Zolmitriptan (I) having desired purity. The invention specifically relates to a method for isolating (S)-4-(4-hydrazinobenzyl)-1,3-oxazolidin-2-one hydrochloride (IIIa) of desired purity by separating the undesired inorganic side products such as stannous hydroxide by manipulation of pH at different stages and finally treating with N,N-dimethylamino butyraldehyde diethyl acetal in an acidic medium to provide Zolmitriptan (I) conforming to regulatory specifications.

Process for preparation of zolmitriptan

Disclosed is process for the preparation of a key Rilpivirine intermediate namely, (E)-4-(2-cyanoethenyl)-2,6-dimethylphenylamine hydrochloride (II) by a process comprising reaction of the tetrafluoroborate salt of the diazonium ion of 2,6-dimethyl-4-amino-1-carboxybenzyl phenylamine (VI) with acrylonitrile in presence of palladium acetate, followed by treatment with an acid and its subsequent conversion to the hydrochloride salt (II), wherein the undesired Z isomer is less than 0.5% and provides Rilpivirine hydrochloride having Z isomer less than 0.1%.

Rilpivirine process

The present invention provides a simple and efficient method for synthesis of 4-[bis(2-chloroethyl)-amino]-L-phenylalanine hydrochloride. The process involves the treatment of 4-[bis(2-chloroethyl)-amino]-L-phenylalanine free base with hydrochloric acid in water followed by isolation of 4-[bis(2-chloroethyl)-amino]-L-phenylalanine hydrochloride of desired purity.

Process for the preparation of melphalan hydrochloride

The present disclosure relates to processes for the preparation of taxane derivatives with improved purity and enhanced stability. The taxane derivatives prepared according to the processes described herein are useful for the preparation of pharmaceutical compositions.

Process for preparation of taxane derivatives

The present invention provides a simple method for preparation of benzphetamine and its acid addition salt comprising reaction of methamphetamine hydrochloride of formula (III) with benzyl chloride and treating the isolated benzphetamine of formula (II) with an acid dissolved in an organic solvent to provide benzphetamine acid addition salt, more specifically, benzphetamine hydrochloride of formula (I).

Process for preparation of benzphetamine and its pharmaceutically acceptable salts

Growing community of inventors

Maharashtra, India

Samit Satish Mehta